Rosolutamide
Based on 1 Customer Validation
Rosolutamide (ASC-JM17) is an orally active Nrf1/Nrf2 activator. Rosolutamide activates Hsf1 pathways, upregulates proteasome subunits and antioxidant enzymes, induces proteasome complex structural rearrangement, and enhances ubiquitin-proteasome system-mediated degradation. Rosolutamide reduces mutant androgen receptor and ataxin-3 aggregates, restores mitochondrial function, attenuates reactive oxygen species (ROS) levels, induces apoptosis and ferroptosis, and inhibits cancer cell growth. Rosolutamide can be used for the research of spinal and bulbar muscular atrophy, Huntington’s disease, and temozolomide-resistant glioblastoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : ≥98.0%
- CAS 番号: 1039760-91-2
- 分子式: C28H32O6
- 分子量:464.55
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
生物活性
製品説明
IC50 & Target
|
HSF1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Glioblastoma cell line | IC50 |
2 μM
Compound: 34; ALZ003
|
Induction of ferroptosis in human primary glioblastoma cells assessed as decrease in GPX4 protein expression incubated for 48 hrs by Western blot analysis
Induction of ferroptosis in human primary glioblastoma cells assessed as decrease in GPX4 protein expression incubated for 48 hrs by Western blot analysis
|
[PMID: 36332549] |
| U-87MG ATCC | IC50 |
<5 μM
Compound: 34; ALZ003
|
Induction of ferroptosis in human U-87 MG cells assessed as decrease in GPX4 protein expression incubated for 48 hrs by Western blot analysis
Induction of ferroptosis in human U-87 MG cells assessed as decrease in GPX4 protein expression incubated for 48 hrs by Western blot analysis
|
[PMID: 36332549] |
体外実験
Rosolutamide (0.2-5 μM; 0-12 h) accelerates UPS-mediated clearance of wild-type and polyglutamine-expanded androgen receptor in healthy control and SBMA fibroblasts, reducing AR steady-state levels and half-life[1].
Rosolutamide (5 μM) inhibits the transcriptional activity of wild-type and polyglutamine-expanded androgen receptor in DHT-treated PC12 cells[1].
Rosolutamide (0-40 μM) potently activates the heat shock response pathway in PC12 cells[1].
Rosolutamide (0-7.5 μM) activates Nrf1 to increase expression of multiple proteasome subunits in PC12 and MCF7 cells[1].
Rosolutamide enhances chymotrypsin-like, trypsin-like, and caspase-like proteasome catalytic activities in PC12 cells[1].
Rosolutamide (0-7.5 μM) activates Nrf2 to increase expression of antioxidant enzymes HO-1, Nqo1, Gclc, and catalase in PC12 cells without inducing global oxidative protein damage[1].
Rosolutamide (2.5 μM; 16 h) protects MCF7 cells against hydrogen peroxide-induced oxidative stress via Nrf2 activation[1].
Rosolutamide (0-7.5 μM) activates Hsf1 to increase expression of heat shock proteins Hsp25, Hsp40, Hsp72, Hsp90, and co-chaperone Hop in PC12 and MCF7 cells[1].
Rosolutamide (0.3-5 µM; 24 h) shows no cytotoxicity in WT, MJD26, and MJD78 cells, but induces cytotoxicity at concentrations greater than 5 µM in WT and MJD78 cells[3].
Rosolutamide (0.3-5 µM; 24 h) improves mitochondrial respiration function in MJD78 cells[3].
Rosolutamide (0.3-5 µM; 24 h) reduces mutant ataxin-3 protein expression and protein aggregation in MJD78 cells via induction of autophagy, with no effect on ATXN3 mRNA levels[3].
Rosolutamide (0.3-5 µM; 24 h) reduces oxidative stress in MJD78 cells by lowering total and mitochondrial ROS levels, and enhances antioxidant defenses by increasing NQO1, HO-1, SOD2, GSH, and catalase, with 1 µM showing the strongest effects[3].
Rosolutamide (0.3-5 µM; 24 h) activates Nrf2 in a dose-dependent manner in MJD78 cells, increasing Nrf2 transcriptional activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Healthy control fibroblasts, SBMA fibroblasts, PC12 cells
-
Concentration:0.5; 1; 2; 2.5; 5 μM
-
Incubation Time:0; 2; 4; 6; 8; 12 h
-
Result:Reduced steady-state levels of both normal and polyglutamine-expanded AR variants in the presence and absence of DHT.
Was effective at lower concentrations than ASC-J9 for reducing mutant AR protein.
Significantly reduced the half-life of polyglutamine-expanded AR compared to DMSO vehicle.
Induced ubiquitylation of both wild-type and mutant AR.
Promoted proteasome-mediated clearance of AR, which was blocked by epoxomicin.
-
Cell Line:wild-type SK-N-SH human neuroblastoma cells, SK-N-SH cells stably expressing ataxin-3 with 26 CAG repeats (MJD26), SK-N-SH cells stably expressing ataxin-3 with 78 CAG repeats (MJD78)
-
Concentration:0.3; 1; 5 µM
-
Incubation Time:24 h
-
Result:Caused no cytotoxicity in WT, MJD26, or MJD78 cells at 0.3, 1, or 5 µM after 24 h.
Increased cytotoxicity in WT and MJD78 cells at concentrations >5 µM after 24 h.
-
Cell Line:MJD78 human neuroblastoma cells
-
Concentration:0.3; 1; 5 µM
-
Incubation Time:24 h
-
Result:Had no significant effect on ATXN3 mRNA levels in MJD78 cells.
Reduced protein aggregation and mutant ataxin-3 protein expression, while upregulating p62 and LC3 II protein expression in MJD78 cells at 0.3 µM and 1 µM.
体内実験
Rosolutamide (120 mg/kg; i.g.; daily; 6 weeks or 16 weeks) ameliorates disease manifestations, reduces mutant AR accumulation, and activates Nrf1/Nrf2 pathways in symptomatic AR97Q mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:transgenic lines: GMR:UAS-AR52Q, Elav-GAL4/UAS-AR52Q/Cyo-GFP (expressing full-length human AR with expanded polyglutamine tract (AR52Q) under GMR-GAL4 eye-specific driver or Elav-GAL4 pan-neuronal driver, treated with 1 mM DHT to induce toxicity)[1]
-
Dosage:50 nM
-
Administration:incorporated into fly food; continuous exposure throughout development/ adulthood
-
Result:Rescued DHT-induced degenerative eye phenotype in GMR:UAS-AR52Q flies.
Significantly increased the population frequency of Elav > AR52Q flies from ~4% (DHT-only) to ~20% (DHT + ASC-JM17).
Failed to rescue the eye phenotype in CncC RNAi lines, but fully restored the eye phenotype in HSF RNAi lines.
-
Animal Model:F1 transgenic mice (AR97Q line, C57Bl6 × BDF1 background; male, post-disease onset at 10 weeks of age) with Spinal and bulbar muscular atrophy (SBMA)[1]
-
Dosage:120 mg/kg
-
Administration:i.g.; daily; 6 weeks or 16 weeks
-
Result:Significantly rescued weight loss and improved motor function.
Ameliorated neurogenic and myogenic muscle atrophy features on H&E and NADH-stained quadriceps cross-sections.
Reduced monomeric and high molecular weight (HMW) mutant AR protein levels in quadriceps muscle.
Significantly increased mRNA expression of Nrf1 target genes (Psmb4, Psmc1, Psmd14; P < 0.01) and Nrf2 target genes (Gsr, Gsta2, Nqo1) in quadriceps muscle.
In a post hoc analysis excluding severely affected mice, increased median survival by ~10 weeks.
化学情報
-
CAS 番号 1039760-91-2
-
性状 Solid
-
分子量 464.55
-
分子式 C28H32O6
-
Color Light yellow to yellow
-
SMILES
COC(C=C1/C=C/C(C(C(/C=C/C2=CC(OC)=C(C=C2)OC)=O)CC3CCC3)=O)=C(C=C1)OC
-
別名
ASC-JM17; ALZ-003
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (107.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Bott LC, et al. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Hum Mol Genet. 2016;25(10):1979-1989. [Content Brief]
[2]. Sedlacek J. Activation of the 26S Proteasome to Reduce Proteotoxic Stress and Improve the Efficacy of PROTACs. ACS Pharmacol Transl Sci. 2024 Dec 16;8(1):21-35. [Content Brief]
[3]. Wu YL, et al. In Vitro Efficacy and Molecular Mechanism of Curcumin Analog in Pathological Regulation of Spinocerebellar Ataxia Type 3. Antioxidants (Basel). 2022;11(7):1389. Published 2022 Jul 18. [Content Brief]
[4]. Osifová Z, et al. Diketo-Ketoenol Tautomers in Curcuminoids: Synthesis, Separation of Tautomers, and Kinetic and Structural Studies. J Org Chem. 2022 Aug 5;87(15):10309-10318. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1526 mL | 10.7631 mL | 21.5262 mL | 53.8155 mL |
| 5 mM | 0.4305 mL | 2.1526 mL | 4.3052 mL | 10.7631 mL | |
| 10 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL | 5.3816 mL | |
| 15 mM | 0.1435 mL | 0.7175 mL | 1.4351 mL | 3.5877 mL | |
| 20 mM | 0.1076 mL | 0.5382 mL | 1.0763 mL | 2.6908 mL | |
| 25 mM | 0.0861 mL | 0.4305 mL | 0.8610 mL | 2.1526 mL | |
| 30 mM | 0.0718 mL | 0.3588 mL | 0.7175 mL | 1.7939 mL | |
| 40 mM | 0.0538 mL | 0.2691 mL | 0.5382 mL | 1.3454 mL | |
| 50 mM | 0.0431 mL | 0.2153 mL | 0.4305 mL | 1.0763 mL | |
| 60 mM | 0.0359 mL | 0.1794 mL | 0.3588 mL | 0.8969 mL | |
| 80 mM | 0.0269 mL | 0.1345 mL | 0.2691 mL | 0.6727 mL | |
| 100 mM | 0.0215 mL | 0.1076 mL | 0.2153 mL | 0.5382 mL |
Keywords
- Rosolutamide
- 1039760-91-2
- ASC-JM17
- ALZ-003
- ALZ003
- ALZ 003
- ALZ-003
- Keap1-Nrf2
- Androgen Receptor
- HSP
- Mitophagy
- Ferroptosis
- Apoptosis
- Reactive Oxygen Species (ROS)
- Autophagy
- ataxin-3 aggregates
- spinal and bulbar muscular atrophy
- Nrf2
- Nrf1
- mutant androgen receptor
- spinocerebellar ataxia
- temozolomide-resistant glioblastoma
- ubiquitin-proteasome system
- Hsf1
- Huntington’s disease
- Inhibitor
- inhibitor
- inhibit